BACKGROUND: Lambda interferons (IFNLs) have potent antiviral activity against HCV, and polymorphisms within the IFNL gene cluster near the IFNL3 gene strongly predict spontaneous- and treatment-related HCV infection outcomes. The mechanism(s) linking IFNL polymorphisms and HCV control is currently elusive. METHODS: IFNL induction was studied in primary human hepatocytes (PHH) from 18 human donors, peripheral blood mononuclear cells (PBMCs) from 18 human donors, multiple cell lines and induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-hepatocytes) from 7 human donors. After stimulation with intracellular RNA and infectious HCV, quantitative PCR (qPCR) primers and probes were designed to distinguish and quantify closely related IFNL messenger (m)RNAs from IFNL1, IFNL2 and IFNL3. RESULTS: PHH demonstrated the most potent induction of IFNLs, although had lower pre-stimulation levels compared to PBMCs, monocytes and cell lines. PHH stimulation with cytoplasmic poly I:C induced >1,000-fold expression of IFNL1, IFNL2 and IFNL3. PHH from donors who were homozygous for the favourable IFNL3 allele (IFNL3-CC) had higher IFNL3 induction compared to PHH from IFNL3-TT donors (P=0.03). Baseline IFNL mRNA expression and induction was also tested in iPSC-hepatocytes: iPSC-hepatocytes had significantly higher baseline expression of IFNLs compared to PHH (P<0.0001), and IFNL3 induction was marginally different in iPSC-hepatocytes by IFNL genotype (P=0.07). CONCLUSIONS: Hepatocytes express IFNLs when stimulated by a synthetic viral RNA that signals the cell through the cytoplasm. IFNL induction may be greater in persons with the favourable IFNL3 allele. These data provide insight into the strong linkage between IFNL3 genetics and control of HCV infection.
BACKGROUND: Lambda interferons (IFNLs) have potent antiviral activity against HCV, and polymorphisms within the IFNL gene cluster near the IFNL3 gene strongly predict spontaneous- and treatment-related HCV infection outcomes. The mechanism(s) linking IFNL polymorphisms and HCV control is currently elusive. METHODS: IFNL induction was studied in primary human hepatocytes (PHH) from 18 human donors, peripheral blood mononuclear cells (PBMCs) from 18 human donors, multiple cell lines and induced pluripotent stem cell-derived hepatocyte-like cells (iPSC-hepatocytes) from 7 human donors. After stimulation with intracellular RNA and infectious HCV, quantitative PCR (qPCR) primers and probes were designed to distinguish and quantify closely related IFNL messenger (m)RNAs from IFNL1, IFNL2 and IFNL3. RESULTS: PHH demonstrated the most potent induction of IFNLs, although had lower pre-stimulation levels compared to PBMCs, monocytes and cell lines. PHH stimulation with cytoplasmic poly I:C induced >1,000-fold expression of IFNL1, IFNL2 and IFNL3. PHH from donors who were homozygous for the favourable IFNL3 allele (IFNL3-CC) had higher IFNL3 induction compared to PHH from IFNL3-TT donors (P=0.03). Baseline IFNL mRNA expression and induction was also tested in iPSC-hepatocytes: iPSC-hepatocytes had significantly higher baseline expression of IFNLs compared to PHH (P<0.0001), and IFNL3 induction was marginally different in iPSC-hepatocytes by IFNL genotype (P=0.07). CONCLUSIONS: Hepatocytes express IFNLs when stimulated by a synthetic viral RNA that signals the cell through the cytoplasm. IFNL induction may be greater in persons with the favourable IFNL3 allele. These data provide insight into the strong linkage between IFNL3 genetics and control of HCV infection.
Authors: Tom W Chu; Rohit Kulkarni; Edward J Gane; Stuart K Roberts; Catherine Stedman; Peter W Angus; Brett Ritchie; Xiao-Yu Lu; David Ipe; Uri Lopatin; Soren Germer; Victor A Iglesias; Robert Elston; Patrick F Smith; Nancy S Shulman Journal: Gastroenterology Date: 2012-01-13 Impact factor: 22.682
Authors: Ludmila Prokunina-Olsson; Brian Muchmore; Wei Tang; Ruth M Pfeiffer; Heiyoung Park; Harold Dickensheets; Dianna Hergott; Patricia Porter-Gill; Adam Mumy; Indu Kohaar; Sabrina Chen; Nathan Brand; McAnthony Tarway; Luyang Liu; Faruk Sheikh; Jacquie Astemborski; Herbert L Bonkovsky; Brian R Edlin; Charles D Howell; Timothy R Morgan; David L Thomas; Barbara Rehermann; Raymond P Donnelly; Thomas R O'Brien Journal: Nat Genet Date: 2013-01-06 Impact factor: 38.330
Authors: Charles D Howell; Alexis Gorden; Kathleen A Ryan; Alexander J Thompson; Chadi Ibrahim; Michael Fried; Nezam H Afdhal; John G McHutchison; Kevin V Shianna; David B Goldstein; Alan R Shuldiner; Braxton D Mitchell Journal: J Hepatol Date: 2011-10-23 Impact factor: 25.083
Authors: Susanna Naggie; Anu Osinusi; Antonios Katsounas; Richard Lempicki; Eva Herrmann; Alexander J Thompson; Paul J Clark; Keyur Patel; Andrew J Muir; John G McHutchison; Joerg F Schlaak; Martin Trippler; Bhavana Shivakumar; Henry Masur; Michael A Polis; Shyam Kottilil Journal: Hepatology Date: 2012-07-02 Impact factor: 17.425
Authors: Xianfang Wu; Jason M Robotham; Emily Lee; Stephen Dalton; Norman M Kneteman; David M Gilbert; Hengli Tang Journal: PLoS Pathog Date: 2012-04-05 Impact factor: 6.823
Authors: Priya Duggal; Chloe L Thio; Genevieve L Wojcik; James J Goedert; Alessandra Mangia; Rachel Latanich; Arthur Y Kim; Georg M Lauer; Raymond T Chung; Marion G Peters; Gregory D Kirk; Shruti H Mehta; Andrea L Cox; Salim I Khakoo; Laurent Alric; Matthew E Cramp; Sharyne M Donfield; Brian R Edlin; Leslie H Tobler; Michael P Busch; Graeme Alexander; Hugo R Rosen; Xiaojiang Gao; Mohamed Abdel-Hamid; Richard Apps; Mary Carrington; David L Thomas Journal: Ann Intern Med Date: 2013-02-19 Impact factor: 25.391
Authors: Jin Ho Kwak; Jin Hyuk Paek; Gyeong Im Yu; Seungyeup Han; Woo Yeong Park; Yaerim Kim; Dong Hoon Shin; Kyubok Jin Journal: Kidney Res Clin Pract Date: 2022-02-23